EMBL is an intergovernmental organisation founded with the mission of promoting molecular biology research in Europe, training young scientists, and developing new technologies.EMBL currently employs more than 1800 people in Barcelona, ​​Grenoble, Hamburg, Heidelberg, EMBL-EBI Hinxton (near Cambridge), and Rome.


The IBS is a mixed research unit (UMR 5075) jointly operated by two French national research agencies (the CEA and the CNRS) and the University Grenoble Alpes ( UGA). The mission of the IBS is to develop research in integrated structural biology to address questions in basic and applied science.


The European Synchrotron Radiation Facility is a joint research facility situated in Grenoble, France, supported by 22 countries. Some 8,000 scientists visit this particle accelerator each year, conducting upwards of 2,000 experiments and producing around 1,800 scientific publications.


The Partnership for Structural Biology (PSB) was established by a Memorandum of Understanding in 2002 by the European Molecular Biology Laboratory ( EMBL), the European Synchrotron Radiation Facility ( ESRF), the Institut Laue Langevin ( ILL) and the Institut de Biologie Structurale ( IBS) to provide a unique environment for state-of-the-art integrated structural biology.


The Grenoble Alliance for Integrated Structural & Cell Biology (GRAL) is a consortium of 5 research institutes (BioSanté, BGE, IBS, LCBM, and LPCV). GRAL was selected for funding as a Laboratoire d’excellence (Labex) through the “Investissements d’avenir” programme of the French government in 2011. GRAL’s funding has been extended until 2028 through the Chemistry, Biology and Health Graduate School of Université Grenoble Alpes.